NRx Pharmaceuticals (NASDAQ:NRXP) today reported its financial results and operational milestones for the full year ended December 31, 2025, highlighting a successful restructuring of its balance sheet and the transition into a revenue-generating entity.
Concentrix (NASDAQ:CNXC) today reported its financial results for the fiscal first quarter ended February 28, 2026, demonstrating steady top-line expansion and a continued commitment to shareholder returns.
Core & Main (NYSE:CNM) today reported financial results for the fourth quarter and fiscal year ended February 1, 2026, showcasing a year of disciplined margin management and robust cash generation.
Fennec Pharmaceuticals (NASDAQ:FENC) today reported its financial results for the fourth quarter and full year ended December 31, 2025, highlighting a year of aggressive commercial scaling and a total recapitalization of the company’s balance sheet.
Achieve Life Sciences (NASDAQ:ACHV) today reported its financial results for the fourth quarter and full year ended December 31, 2025, alongside a series of transformative regulatory and operational updates for its lead smoking cessation candidate, cytisinicline.
Karyopharm Therapeutics (NASDAQ:KPTI) today announced topline results from its global Phase 3 SENTRY clinical trial (n=353) evaluating the XPO1 inhibitor selinexor in combination with ruxolitinib (Jakafi®) for the frontline treatment of patients with myelofibrosis.
LightInTheBox Holding (NYSE:LITB) today announced its unaudited financial results for the fourth quarter and full year ended December 31, 2025, marking a definitive shift from high-volume scaling to high-margin profitability.
VersaBank (NASDAQ:VBNK) today announced it has reached a definitive agreement to sell the assets associated with its sole U.S. retail branch in Holdingford, Minnesota, to Stearns Bank National Association.
The Buckle (NYSE:BKE) today announced that its Board of Directors has authorized a quarterly cash dividend of $0.35 per share.
BioNTech (NASDAQ:BNTX) announced today its comprehensive participation in the European Lung Cancer Congress (ELCC) 2026, where the company will present updated data across its diversified lung cancer portfolio.
UTStarcom (NASDAQ:UTSI) today reported its unaudited financial results for the six months and full year ended December 31, 2025, revealing a challenging fiscal year defined by a significant contraction in its primary geographic markets.
Radiopharm Theranostics (NASDAQ:RADX) today released a highly encouraging second interim data update from its ongoing U.S. Phase 2b clinical trial evaluating RAD 101, a novel FASN-targeting small-molecule imaging agent.
